Yuanqing Li

Discovery of selective CDK9 degraders with enhancing antiproliferative activity through PROTAC conversion.

Jie Ren, H. Ding, Zhiyu Li, 2020, European journal of medicinal chemistry.

Design, synthesis, and biological evaluation of 4-benzoylamino-1H-pyrazole-3-carboxamide derivatives as potent CDK2 inhibitors.

Kaixian Chen, Hualiang Jiang, C. Luo, 2021, European journal of medicinal chemistry.

Design, synthesis and biological evaluation of a novel spiro oxazolidinedione as potent p300/CBP HAT inhibitor for the treatment of ovarian cancer

Kaixian Chen, C. Luo, H. Ding, 2021, Bioorganic & Medicinal Chemistry.

Structure-Guided Development of Small-Molecule PRC2 Inhibitors Targeting EZH2-EED Interaction.

Kaixian Chen, Hualiang Jiang, J. Min, 2021, Journal of medicinal chemistry.

Discovery of a highly potent NPAS3 heterodimer inhibitor by covalently modifying ARNT.

Dalei Wu, C. Luo, H. Ding, 2023, Bioorganic chemistry.

Structural Mass Spectrometry Probes the Inhibitor-Induced Allosteric Activation of CDK12/CDK13-Cyclin K Dissociation.

Ch Lai, Fangjun Wang, Xueming Yang, 2023, Journal of the American Chemical Society.

Lead discovery, chemical optimization, and biological evaluation studies of novel histone methyltransferase SET7 small-molecule inhibitors.

C. Luo, H. Ding, Rukang Zhang, 2020, Bioorganic & medicinal chemistry letters.